Biogen Idec opens new US facility
Biogen Idec has opened a new facility focusing on patient care in RTP, North Carolina.
Independent biotech company Biogen Idec has opened a new facility in Research Triangle Park (RTP), a large research park in the US state of North Carolina.
The new 190,000 sq ft building has enabled the company to consolidate its patient services operations, bringing together more than 1,000 people in one state.
Increasing levels of manufacturing activity will be accommodated at the site and the company expects it to achieve LEED-Gold certified status in a matter of months.
Dr George Scangos, chief executive officer for Biogen Idec, said: "The expansion of our footprint in RTP underscores our commitment to providing a secure supply of medicines and to helping patients overcome obstacles to receiving them."
Machelle Sanders, vice-president of manufacturing and general manager for Biogen Idec RTP, added that the site will focus on patient care, ranging from manufacturing high-quality therapies through to providing patient support and financial assistance.
Biogen Idec is now the ninth largest employer in RTP and the second largest independent biotech company in North Carolina, manufacturing Avonex (interferon beta-1a) and Tysabri (natalizumab) for multiple sclerosis, as well as several other clinical products.
Related News
-
News Novartis signs US$3.2 bn subcutaneous delivery deal with Alteogen
Swiss pharma giant secures access to Korean biotech's ALT-B4 hyaluronidase platform in milestone-heavy agreement, marking Alteogen's fourth major licensing deal of 2026 as competition intensifies in the subcutaneous drug delivery space.
-
News Women in Pharma: The philosophy of pharmaceutical leadership
In this latest instalment of our Women in Pharma series, we sit down with Clarissa Sowemimo-Coker, Chief Strategy Officer at Ambrose Healthcare and CPHI Middle East Advisory Board Member.
-
News The PSCI Supplier Partnership - Collaboration for Responsible Supply Chains
About the Pharmaceutical Supply Chain Initiative The Pharmaceutical Supply Chain Initiative (PSCI) is the leading, member-led association for pharmaceutical companies working collaboratively to build responsible supply chains. Founded in 2006 and es... -
News AstraZeneca shares plunge 8.9% after reports of BMS talks
Britain's largest drugmaker lost more than GBP£17 billion in market value following reports of preliminary merger discussions with Bristol Myers Squibb that could create a pharmaceutical giant worth nearly US$400 billion, though investors rem... -
News GSK announces £400 million investment in new Cambridge R&D centre
Pharmaceutical giant to establish flagship research facility on Cambridge Biomedical Campus as part of strategic pipeline acceleration
-
News The CPHI Sustainability Summit - Where Conversation Becomes Collaboration
The Report Was Never the Destination - “The future of pharmaceutical sustainability won’t be shaped by individual organisations working in isolation. It will be shaped by partnerships, shared expertise and the willingness to work diffe... -
News Trump's generic drug tariffs set to reshape global pharmaceutical supply chains
The US president has announced plans to impose tariffs of up to 200% on imported generic medicines from August 2028, giving manufacturers a two-year window to establish domestic production facilities. The move threatens to upend a global supply chain t... -
News Building Safer, More Responsible Pharmaceutical Supply Chains: PSCI Global Audit Insights
The Pharmaceutical Supply Chain Initiative (PSCI) has released its seventh annual Audit Findings Analysis Report, offering unprecedented insights into supplier practices across the global pharmaceutical and healthcare industry.With a record-breaking 24...